In ongoing clinical trials, glutamate receptor (mGLUR5) modulators and AMPA/kainite receptor antagonists are promising treatments for acute migraine, as are NMDA and kainate receptor antagonists for migraine prophylaxis. The gene discussed is GRM5; the disease is migraine disorder.